Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDLTSE:HLSTSE:LABSCVE:RX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.25-0.4%$1.05$0.77▼$3.12$103.26M0.98359,800 shs115,484 shsHLSHLS TherapeuticsC$4.90-1.0%C$4.46C$3.00▼C$5.23C$109.01M1.0713,259 shs3,416 shsLABSMediPharm LabsC$0.08+7.1%C$0.09C$0.06▼C$0.12C$31.13M0.88350,563 shs202,354 shsRXBioSyentC$11.80+0.5%C$10.90C$8.97▼C$12.13C$134.96M0.934,752 shs524 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics0.00%+13.18%+11.16%+8.26%-48.13%HLSHLS Therapeutics0.00%+4.70%+12.39%+16.95%+22.50%LABSMediPharm Labs0.00%0.00%-11.76%0.00%-6.25%RXBioSyent0.00%-1.26%+9.26%+5.36%+26.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.4268 of 5 stars3.74.00.00.02.10.00.6HLSHLS Therapeutics0.198 of 5 stars1.00.01.70.00.01.70.0LABSMediPharm LabsN/AN/AN/AN/AN/AN/AN/AN/ARXBioSyentN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.40Buy$8.67596.12% UpsideHLSHLS Therapeutics 2.00HoldC$4.50-8.16% DownsideLABSMediPharm Labs 0.00N/AN/AN/ARXBioSyent 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LABS, CRDL, RX, and HLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/26/2025HLSHLS TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHoldC$3.50 ➝ C$4.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AHLSHLS TherapeuticsC$40.13M2.72C$0.32 per share15.22C$2.51 per share1.95LABSMediPharm LabsC$39.42M0.79C$0.06 per share1.30C$0.11 per share0.68RXBioSyentC$34.06M3.96C$3.84 per share3.07C$3.22 per share3.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)HLSHLS Therapeutics-C$15.53M-C$1.00N/A∞N/A-38.70%-25.27%-2.89%N/ALABSMediPharm Labs-C$12.05M-C$0.03N/A∞N/A-30.56%-24.41%-7.17%N/ARXBioSyentC$7.02MC$0.6219.15∞N/A20.60%20.01%12.86%N/ALatest LABS, CRDL, RX, and HLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AHLSHLS TherapeuticsC$0.204.08%N/AN/A N/ALABSMediPharm LabsN/AN/AN/AN/AN/ARXBioSyentC$0.181.53%N/A29.21%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.492.49HLSHLS Therapeutics86.501.561.01LABSMediPharm Labs1.453.213.10RXBioSyent2.903.926.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%HLSHLS Therapeutics65.20%LABSMediPharm Labs0.71%RXBioSyent1.37%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%HLSHLS Therapeutics0.37%LABSMediPharm Labs4.45%RXBioSyent33.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableHLSHLS Therapeutics9122.25 millionN/ANot OptionableLABSMediPharm Labs130415.00 millionN/ANot OptionableRXBioSyentN/A11.44 millionN/ANot OptionableLABS, RX, CRDL, and HLS HeadlinesRecent News About These CompaniesBloom Burton Forecasts BioSyent's FY2025 Earnings (CVE:RX)May 24, 2025 | marketbeat.comBloom Burton Forecasts BioSyent's FY2026 Earnings (CVE:RX)May 23, 2025 | marketbeat.comFY2026 Earnings Estimate for BioSyent Issued By Bloom BurtonMay 23, 2025 | americanbankingnews.comFY2025 Earnings Forecast for BioSyent Issued By Bloom BurtonMay 23, 2025 | americanbankingnews.comBioSyent (CVE:RX) Has Announced A Dividend Of CA$0.05May 19, 2025 | finance.yahoo.comBioSyent (CVE:RX) Share Price Crosses Above 50 Day Moving Average - Time to Sell?May 18, 2025 | marketbeat.comHere's Why We Think BioSyent (CVE:RX) Is Well Worth WatchingMay 15, 2025 | finance.yahoo.comCould The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?April 18, 2025 | finance.yahoo.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive YearApril 1, 2025 | markets.businessinsider.comFAX Capital Corp. Sells 112,400 Shares of BioSyent Inc. (CVE:RX) StockDecember 24, 2024 | insidertrades.comInvesting in BioSyent (CVE:RX) five years ago would have delivered you a 110% gainDecember 15, 2024 | uk.finance.yahoo.comBioSyent Inc. (CVE:RX) Senior Officer Sells C$55,628.75 in StockDecember 13, 2024 | insidertrades.comInsider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of StockNovember 27, 2024 | insidertrades.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 SharesNovember 26, 2024 | insidertrades.comBioSyent Inc. (RX.V)November 25, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four DaysNovember 24, 2024 | finance.yahoo.comCalculating The Fair Value Of BioSyent Inc. (CVE:RX)November 22, 2024 | finance.yahoo.comBioSyent Inc. (BIOYF)November 21, 2024 | finance.yahoo.comBioSyent Inc.November 13, 2024 | wsj.comAMD RDNA 4: everything we know so far about the RX 8000 seriesNovember 1, 2024 | digitaltrends.comBioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?October 24, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLABS, RX, CRDL, and HLS Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.25 -0.01 (-0.40%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.25 0.00 (0.00%) As of 05/30/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.HLS Therapeutics TSE:HLSC$4.90 -0.05 (-1.01%) As of 05/30/2025 03:47 PM EasternHLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.MediPharm Labs TSE:LABSC$0.08 +0.01 (+7.14%) As of 05/30/2025 12:04 PM EasternMediPharm Labs Corp, along with its subsidiaries, produces purified, pharmaceutical-like cannabis extracts and related derivative products. The company generates revenue from Private label, White label, the Tolling process, and others. Some of its vape brands are Northern Lights, Blue Dream Pink Kush and GG4. Its geographical segments are Canada and Australia.BioSyent CVE:RXC$11.80 +0.06 (+0.51%) As of 05/30/2025 02:13 PM EasternBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
